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Abstract
Implicating particular genes in the generation of complex brain and behavior phenotypes requires
multiple lines of evidence. The rarity of most high impact genetic variants typically precludes the
possibility of accruing statistical evidence that they are associated with a given trait. We show
here that the enrichment of a rare Chromosome 22q11.22 deletion in a recently expanded Northern
Finnish sub-isolate enables the detection of association between TOP3β and both schizophrenia
and cognitive impairment. Biochemical analysis of TOP3β revealed that this topoisomerase is a
component of cytosolic messenger ribonucleoproteins (mRNPs) and is catalytically active on
RNA. The recruitment of TOP3β to mRNPs was independent of RNA cis-elements and was
coupled to the co-recruitment of FMRP, the disease gene product in fragile X mental retardation
syndrome (FXS). Thus, we uncover a novel role for TOP3β in mRNA metabolism and provide
several lines of evidence implicating it in neurodevelopmental disorders.
Introduction
Disruptions in messenger RNA (mRNA) metabolism play an important role in the etiology
of human disease1. Genetic studies have identified disease-causing mutations in several
known mRNA binding proteins, while molecular biology approaches have connected
disease genes of unknown function to mRNA metabolism. Here, we combine both methods
to show that deletion of the topoisomerase TOP3β is associated with neurodevelopmental
disorders, and identify a function for this DNA-processing enzyme in mRNA metabolism.
The Finnish disease heritage (FDH) refers to rare Mendelian disorders (http://
www.findis.org/) that are more prevalent in Finland than elsewhere in the world and that
vary substantially in frequency between different parts of Finland. This variation reflects
extreme genetic drift at the causative loci, due to multiple population bottlenecks that have
generated sub-isolates within the overall Finnish isolate, in particular in Northeastern
Finland2, 3. Drift can also dramatically elevate the frequencies, in such isolates, of rare
alleles with a high impact on common traits2. It is unlikely that any single variant could
substantially influence the overall population risk for specific disorders, such as
schizophrenia. We hypothesized, however, that enrichment in Northern Finland for multiple
high-impact variants could contribute to an increased frequency of particular classes of
disorders in this region compared to other parts of country, acting along with environmental
influences such as socioeconomic factors4, 5.
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The prevalence of several neurodevelopmental phenotypes in Finland follows a striking
gradient from Northeast to Southwest (Fig. 1), as exemplified by schizophrenia, which is
almost three times more prevalent in Northeastern sub-isolates than in Finland overall4, 6, 7.
Considerable evidence supports the association of large deletions, both overall variant
burden as well as specific variants, with a wide range of neurodevelopmental disorders,
including schizophrenia and cognitive impairment8, 9. We previously showed an association
between the burden of large deletions and neurodevelopmental phenotypes in a Northern
Finnish population cohort, and established that several of these deletions represent founder
mutations, carried on haplotypes shared identical by descent10. We hypothesized that some
smaller deletions might be sufficiently increased in frequency in Northern Finland to enable
the detection, by analyses of single-variants, using currently available study samples, of
associations to schizophrenia and other neurodevelopmental phenotypes that are particularly
frequent in this region. As we show here, the enrichment of a rare Chromosome 22q11.22
deletion in the Northern Finnish sub-isolates enabled analyses suggesting TOP3β, which is
wholly contained within the deletion, as a risk gene for neurodevelopmental disorders.
TOP3β encodes the DNA topoisomerase III β. Our biochemical investigations of TOP3β
revealed functions for this protein that could explain the phenotypic impact of its deletion. In
particular, it was strikingly and unexpectedly associated with FMRP, an RNA binding
protein, that normally inhibits the translation of neuronal mRNAs11, 12. The deregulated
expression of these mRNAs, in the absence of this protein is the molecular defect underlying
FXS13 (OMIM#300624). The process through which FMRP-containing mRNPs form
remains ill-defined; however, recent investigations of the functional impact of the highly
pathogenic I304N FMR1 missense mutation suggest that protein-protein interactions may
contribute to the recruitment of FMRP to its target mRNAs14.
Our studies have uncovered a mechanism for such a recruitment: The Tudor domain
containing protein 3 (TDRD3), which itself binds to the exon junction complex (EJC)15
deposited on newly spliced mRNAs, mediates the concomitant integration of TOP3ββ and
FMRP into mRNPs. Our demonstration of TOP3β topoisomerase activity on RNA
substrates suggests its involvement in the metabolism of FMRP-bound mRNAs.. Together
with the results from genetic analyses of the Northern Finnish 22q11.22 deletion and from
independent investigations of de novo TOP3β mutations16-18, this biochemical evidence
indicates the important role of this protein in neurodevelopment.
Results
Identification of deletions enriched in Northern Finland
Using genome-wide SNP arrays, we searched for deletions enriched in the Northeastern sub-
isolates compared to the rest of Finland, in representative samples from each population
(Sub-isolate Population Sample, N=173; Whole Finland Population Sample, N=1586)19, 20,
(see Online Materials and Methods and Table S1 for descriptions of all cohorts used in this
study). To minimize false positives we considered only deletions of > 20 kb in length,
detected with ≥10 probes. We identified, in the combined samples, 5,313 putative deletions
(5,004 heterozygous, 309 homozygous) comprising 1,041 distinct genomic loci, with a mean
size of 89.4 kb.
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Two deletion loci, on chromosomes 4q12 and 22q11.22, displayed significantly higher
frequencies in the Sub-isolate Population Sample compared to the Whole Finland Population
Sample (empirical p-value < 0.001 after 10,000 permutations), were in Hardy-Weinberg
Equilibrium, and were confirmed by manual inspection of intensity distribution plots (Fig.
S1). The 4q12 deletion (181.7 kb) occurred in 6/173 individuals from the Sub-isolate
Population Sample and was not observed in the Whole Finland Population Sample (p=
8.7×10−7, Fisher’s Exact Test) while the 22q11.22 deletion (243.9 kb) occurred in 18/173
individuals from the Sub-isolate Population Sample and only in 1/1586 individuals from the
Whole Finland Population sample (p= 8.55×10−18, Fisher’s Exact Test).
Shared SNP haplotypes among deletion-carriers indicated a single ancestral origin for each
deletion. Carriers of the 4q12 deletion shared a 2.248 Mb haplotype (248 kb proximal and
2.0 Mb distal to the deletion), while carriers of the 22q11.22 deletion shared a 289 kb
haplotype (167 kb proximal and 122 kb distal to the deletion). The presence of the shared 4q
and 22q haplotypes among Finnish non-carriers of the deletions (population frequencies of
1.1% and 13.0%, respectively, assuming full LD between their proximal and distal portions)
indicate that both deletions arose relatively recently.
Neither the 4q12 deletion nor the shared haplotype in this region overlapped with known
genes. The 240 kb 22q11.22 deletion lies within the 1.4 −2.1 Mb distal 22q11.2
microdeletion syndrome region21. Several studies have implicated this region, ~400kb
telomeric to the region deleted in velocardiofacial syndrome (VCFS)22, in both
schizophrenia and developmental delay9, 23, 24. The deletion described here encompasses
two possible genes; TOP3β, is a stable protein-coding gene predicted by all algorithms, and
with an unambiguous genomic position, while IGLV2-14 is a predicted transcript of
unknown function, whose position has shifted between different genome builds, and which
shares sequence homologies with immunoglobulin variants. Two complementary low copy
repeats (chr22:20638870-20642866 and chr22:20904962-20908959) flank the 22q11.22
deletion and likely facilitated its formation (Fig. 2a).
Association of the 22q deletion with schizophrenia
To assess whether the increased frequencies of the 4q12 and 22q11.22 deletions in the
Northeastern sub-isolate are related to risk for neurodevelopmental disorders, we compared
previously genotyped samples; 185 individuals diagnosed with schizophrenia (Sub-isolate
Schizophrenia Sample25) with 747 unscreened controls (Sub-isolate Control Sample). The
22q11.22 deletion showed significantly increased frequency in the Sub-isolate
Schizophrenia Sample (OR = 1.84, p < 0.03), while the 4q12 deletion showed no such
difference (p = 0.14) (Table 1).
We additionally assessed the association between the 22q11.22 deletion and schizophrenia
in case-control samples from other parts of Finland and from elsewhere in Europe, using
large samples given the rarity of the deletion outside of the sub-isolate (Whole Finland
Schizophrenia Sample23 and Whole Finland Control Sample, 467 cases and 11,124 controls;
International Schizophrenia Consortium, ISC23, and Swedish Schizophrenia Consortium,
SSC26, 9176 cases and 9529 controls). The deletion displayed nominal association with
schizophrenia in the Whole Finland samples (OR = 2.63, p = 0.008, after controlling for
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genomic inflation [λ = 1.20]) but not in the non-Finnish samples, although the effect was in
the same direction (OR = 2.17, p= 0.12; Table 1). The combined estimate of significance
was p=0.007 (OR = 1.84, 95%-CI: 1.18 - 2.87), with no heterogeneity of effect observed
between the three samples.
Association of the 22q deletion with cognitive impairment
We analyzed the relationship between the 4q12 and 22q11.22 deletions and seven
neurodevelopmental phenotypes evaluated previously with respect to large deletions in
4,872 genotyped members of the Northern Finland 1966 Birth Cohort (NFBC1966)10, a
geographically representative population cohort, drawn from the Northeastern sub-isolates
as well as the surrounding, less genetically isolated regions; we excluded 59 individuals
diagnosed with schizophrenia who were included in the schizophrenia case-control analyses.
As with the larger deletions investigated previously in NFBC196610, carriers of the
22q11.22 deletion showed significantly higher frequencies of intellectual deficit compared
to non-carriers (OR = 4.6, 95%-CI: 1.41-14.96, p = 0.03), and an even greater
overrepresentation of milder learning difficulties (OR= 5.9, 95%-CI: 1.78-8.94, p=0.003)
(Table 2). The deletion carriers, however, did not show a significantly increased risk for
psychosis (excluding diagnosis of schizophrenia), although the effect was in the predicted
direction (OR = 4.1, 95%-CI: 0.55-30.17, p = 0.2). No phenotypes were significantly
overrepresented among 4q12 deletion carriers.
Cognitive function in schizophrenic deletion carriers
Schizophrenia is associated with cognitive impairments, and this association may reflect a
common genetic basis for these phenotypes27. Given the observed association of the
22q11.22 deletion with both schizophrenia and cognitive impairment, we evaluated
cognitive performance in relation to both diagnosis and deletion status in 566 schizophrenic
subjects (19 deletion carriers and 547 non-carriers), each of whom is the proband in a family
from the Finnish Schizophrenia Family Study (comprising the majority of the individuals in
the Sub-isolate and Whole Finland Schizophrenia Samples). Deletion carriers performed
worse than non-carriers in tests assessing verbal memory after short delay (B = −1.5, p
=0.03) and showed a similar trend for other measures, although not reaching statistical
significance (Table S2). Within the pedigrees of which the 19 deletion carriers are members,
we observe no apparent segregation with neurodevelopmental phenotypes of the 22q11.22
deletion, in heterozygous form (Fig. S2), as expected given the magnitude of the effects
observed in the association analyses.
Phenotypic impact of the 22q deletion, in recessive form
We identified, in NFBC1966 and the Sub-isolate Schizophrenia Sample, four homozygous
carriers of the 22q11.22 deletion, three of whom descended from consanguineous matings
(Fig. 2b). All four individuals displayed cognitive impairment, ranging from poor
performance on tests of executive function and information processing to moderate mental
retardation. Two of them also carried a diagnosis of schizophrenia.
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TOP3β expression is disrupted among 22q deletion-carriers
Given the limited genomic information and lack of prior genetic evidence relating to
IGLV2-14, we chose to focus on TOP3β; prior studies have suggested that de novo TOP3β
mutations may contribute to neurodevelopmental disorders16, 17, and we hypothesized that
disruption of this gene could account for the observed phenotypic effects of the 22q11.22
deletion. Microarray analysis in 65 individuals (51 non carriers, 12 heterozygous carriers,
and two homozygous carriers drawn from 18 families of the Finnish Schizophrenia Family
Study) confirmed the simple dosage-dependent effect of the deletion on TOP3β expression
(probe 4900386, Fig. 2c).
The deletion had no genome-wide significant effect on mRNA levels of other genes, either
in 22q or elsewhere in the genome. However, 813 genes (858 of 9872 probes) showed
nominal difference in mRNA levels between deletion carriers and non-carriers (p<0.05).
From this set of 813 genes, we evaluated whether any functional gene category, plausibly
affected by the down-regulation of TOP3β would be enriched among deletion carriers
compared to non-carriers. Genes involved in two related categories, translation and
ribosomal complexes displayed a 3.1 and a 2.8 -fold enrichment, respectively, (p = 6.2 ×
10−8 and 2.8 × 10−10, Table S3), suggesting the possibility that the 22q11.22 deletion exerts
its phenotypic effect via disturbed translational regulation. We were unable to detect, in
deletion carriers, an enrichment of differentially expressed FMRP target genes12 (data not
shown). For the majority of the FMRP target genes (458/843), expression levels in
peripheral blood were below the threshold for detection. These 458 undetectable genes were,
in contrast to the 385 detected genes, overrepresented in gene categories related to neuronal
functioning, suggesting that this negative result may reflect our lack of the most biologically
relevant tissues for this analysis.
A complex of TOP3β, TDRD3 and FMRP binds early mRNPs
To gain insight into the cellular function of TOP3β we generated a stable cell line allowing
the expression of FLAG/HA-tagged TOP3β. Immunoprecipitations with anti-FLAG
antibodies uncovered an interaction of TOP3β with TDRD3 and FMRP (Fig. 3a). These
proteins co-purified in an RNAse insensitive manner, illustrating a direct rather than RNA-
mediated interaction. TDRD3 is a multidomain protein that, in addition to its EJC-binding
motif (EBM), contains an N-terminal OB-fold domain (NTD) of unknown function and a C-
terminal FMRP-interacting motif (FIM)16, 17. TOP3β bound to the NTD (Fig. S3a-c),
suggesting that TDRD3 is a bridging factor in a heterotrimeric TOP3β-TDRD3-FMRP
(TTF) complex (Fig. S3d). Immunoprecipitation of TOP3β also resulted in the RNAse-
sensitive co-purification of the EJC component MAGOH and the cytosolic poly(A)-binding
protein PABPC1 (Fig. 3a), suggesting that TTF is associated with spliced mRNPs. TTF
exists in mouse brain lysates and NSC-34 cells, indicating its presence in neuronal cells
(Fig. 3b and Fig. S3e).
TOP3β is a stress granule component and binds RNA directly
FMRP and TDRD3 are nucleo-cytoplasmic shuttling proteins and localize predominantly to
the cytosol under steady state conditions14, 28. The identification of TOP3β as an interactor
of these proteins prompted us to analyze its subcellular distribution. Immunofluorescence
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microscopy, expression of GFP-tagged fusion protein and subcellular fractionation all
indicated that TOP3β also is mostly cytosolic (Fig. 3c and S4a, b). In addition, upon arsenite
treatment or strong overexpression, TOP3β co-localized with TDRD3 and FMRP in
cytosolic foci reminiscent of stress granules, storage sites of translationally silenced
mRNAs29 (Fig. 3c and S4c, d). Treatment of cells with the nuclear export-inhibitor
leptomycin-B or deletion of the putative nuclear export signal shifted GFP-TOP3β to the
nucleus (Fig. S4e-g). Thus, all components of the TTF complex exhibit similar intracellular
localization and trafficking. To test whether TOP3β directly associates with mRNAs, we
purified mRNA-bound proteins using oligo(dT)-cellulose, and captured TOP3β, along with
FMRP and PABPC1, in an RNAse sensitive manner (Fig. 3d). In a vice versa experiment,
we performed UV crosslinking and immunoprecipitation and found cellular RNAs
efficiently crosslinked to FLAG/HA-TOP3β (Fig. 3e). These results indicated that TOP3β is
a component of cytosolic mRNPs.
TOP3β is catalytically active on RNA
TOP3β is a type IA topoisomerase that catalyzes transient breakage of a DNA strand by the
reversible transesterification between an active site (AS) tyrosyl and a DNA 5′-phopshoryl
group30. Cleaved intermediates can be released by SDS-denaturation of the enzyme during
its catalytic cycle (Fig. 4a). The ability of TOP3β to directly bind RNA (see Fig. 3e)
encouraged us to test whether TOP3β might be active on RNA substrates. Indeed, the
addition of RNA inhibited cleavage of 5′-labeled DNA by recombinant TOP3β (Fig. 4b),
indicating that both molecules compete for the same active site (Fig. 4c). Also, incubation of
TOP3β with 5′-labeled RNA resulted in a specific cleavage product (Fig. 4d). The
formation of covalent complexes of TOP3β and 3′-labeled RNA was consistent with a 5′-
phosphotyrosyl intermediate (Fig. 4e). Of note, we observed a high molecular weight smear
in Western blot analysis of FLAG/HA-TOP3β oligo(dT)-purified from cellular extracts (Fig.
3d, lane 2). Reasoning that this smear might represent covalent complexes between
FLAG/HA-TOP3β and RNA, we eluted oligo(dT)-purified FLAG/HA-TOP3β from the
column and treated the eluate with RNAse (Fig. 4f). RNAse treatment eliminated the FLAG-
positive high molecular weight species, suggesting that TOP3β is active on mRNA
substrates in vivo.
TTF-containing mRNPs are associated with polyribosomes
To analyze whether TTF-bound mRNPs are associated with the translation machinery, we
first purified translation factors from HeLa cells (Fig. 5a). As reported for FMRP31, TDRD3
and TOP3β were present in crude ribosomal pellets but dissociated upon high-salt treatment
(Fig. 5b), suggesting that they are components of translating mRNPs.
Western blot analysis of polysome gradient centrifugation from stable FLAG/HA-TDRD3
cell extracts showed that FLAG/HA-TDRD3 and endogenous TOP3β co-migrated with
FMRP in polysomal fractions in an RNAse sensitive manner (Fig. 5c), further demonstrating
that part of the TTF-bound mRNP pool is undergoing translation. This observation is
noteworthy considering the binding of TDRD3 to the EJC15, as the latter is thought to be
removed from the mRNA during the first round of translation32. A hallmark of mRNPs that
participate in this “pioneer round” of translation is their association with the nuclear cap
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binding proteins CBP20 and CBP80 instead of eIF4E32. Immunoprecipitation of TTF-
containing mRNPs via FLAG/HA-TDRD3 revealed their binding to CBP20 and CBP80, but
not to eIF4E (Fig. 5d), suggesting that TTF is a component of mRNPs undergoing the
pioneer round of translation.
TTF recruitment to mRNPs requires the TDRD3 Tudor domain
To dissect the mechanisms leading to TTF formation and integration into mRNPs, we
generated TDRD3-mutants in which individual protein-protein interactions were disrupted
(Fig. 6a). We established stable cell lines expressing FLAG/HA-tagged versions of these
mutants and analyzed them by immunoprecipitation as well as polysome gradient
centrifugation. Wildtype TDRD3 formed the TTF complex (Fig. 6b) and became integrated
into polysome-bound mRNPs (Fig. S5a). Deletion of the binding sites for FMRP
(TDRD3ΔFIM) or TOP3β (TDRD3ΔNTD) resulted in the loss of the respective protein from
TTF (Fig. 6b and S5b). However, integration of the remaining binary complexes into
mRNPs and polysomes was unaffected (Fig. 6b and S5a, b), indicating that the recruitment
of TDRD3 to the EJC can occur independently of TTF formation. Mutation of the EBM
(TDRD3EBMmut), in contrast, abolished integration of TDRD3 into mRNPs while binding of
TOP3β and FMRP were unaffected (Fig. 6b and S5a). Thus, formation of the TTF complex
occurs before TDRD3 is tethered to the EJC.
Lastly, we analyzed a missense mutation of the Tudor domain (TDRD3TDRmut), impairing
the recognition of asymmetrically dimethylated arginine (aDMA) modifications in the C-
terminal domain of RNA Polymerase II (RNAPII CTD) and in the tails of Histones H3 and
H4 at the transcription start site (TSS)33, 34. As several mRNA processing factors are
recruited to the nascent transcript via the RNAPII CTD, we reasoned that TDRD3 might
follow a similar route. Indeed, TDRD3TDRmut showed strongly reduced association of
TDRD3 with mRNPs (Fig. 6b and S5a). While this mutation did not affect the assembly of a
TOP3β-TDRD3 heterodimer, it diminished the recruitment of FMRP (Fig. 6b). Thus, the
generation of TTF-containing mRNPs requires the recognition of aDMA by TDRD3.
Although FIM and EBM reside outside of the Tudor domain14, 15, we wanted to exclude the
possibility that the latter contributes to FMRP or EJC binding, as aDMA modifications have
been reported for FMRP and other mRNP components35. We incubated purified TDRD3
with cellular extracts and analyzed for bound FMRP and MAGOH, observing no differences
between wildtype and Tudor mutant protein (Fig. 6c, lanes 2 and 3). This finding was
specific, as TDRD3EBMmut failed to associate with MAGOH (Fig. 6c, lane 4). Therefore,
mutating the Tudor domain per se does not influence the binding of TDRD3 to FMRP or the
EJC. Instead, the defect of TDRD3TDRmut in TTF formation and mRNP incorporation
appears to be a consequence of its impaired binding to aDMA-modified histones and/or
RNAPII.
Formation of TTF containing mRNPs requires TDRD3
The above results uncovered a mechanism for the concomitant integration of TOP3β,
TDRD3 and FMRP into mRNPs. To investigate whether this is the only pathway for the
biogenesis of mRNPs containing TOP3β and FMRP, we used a cell line carrying a deletion
encompassing TDRD336. Gradient centrifugation revealed that in these TDRD3-deficient
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cells, the association of TOP3β with polysomes was diminished (Fig. 6d). However, upon
transfection of FLAG/HA-TDRD3, TOP3β became redistributed into the polysomal
fractions. Thus, TDRD3 is necessary and sufficient for the recruitment of TOP3β to mRNPs.
Overexpressed TDRD3EBMmut was not associated with polysomes and consequently failed
to increase the amount of polysomal TOP3β (Fig. 6d and S6a), indicating that the EJC is the
only docking platform for TTF on mRNPs.
FMRP, by contrast, associated with polysomes in TDRD3-deficient cells (Fig. S6b). This
observation suggested that TTF-containing mRNPs constitute only a subpopulation of the
FMRP-bound pool and implied that alternative routes exist for integrating FMRP into
mRNPs. Hence we analyzed whether the presence of TDRD3 is a prerequisite for
recruitment of FMRP into a specific, TTF-containing mRNP subpopulation. For this
purpose, we transfected TDRD3-deficient cells either with GFP-TOP3β alone or together
with FLAG/HA-TDRD3 variants and assayed them for TTF and mRNP formation via anti-
GFP immunoprecipitations. Consistent with the results shown in Figure 6d, GFP-TOP3β
association with FMRP and mRNPs was entirely dependent on cotransfected wildtype
TDRD3 (Fig. 6e, lanes 6 and 8). In contrast, co-transfection of FLAG/HATDRD3ΔFIM
enabled the formation of mRNPs containing GFP-TOP3β but these mRNPs were entirely
devoid of FMRP (Fig. 6e, lane 7). Together, these data indicated that TDRD3 is essential for
the integration of FMRP into the subpopulation of mRNPs that contain the TTF complex.
Discussion
Our finding of association between neurodevelopmental disorders and a 22q11.22 deletion –
vastly increased in frequency in Northern Finnish sub-isolates and occurring on a single
haplotype – demonstrates the special value of such populations for identifying variants with
a high impact on common phenotypes. Projects underway that aim to comprehensively
genotype a large proportion of the Finnish population37 should be able to exploit such
enrichment of functional variants to identify a wide range of trait-associations that in most
populations could require unfeasibly large samples. As with the 22q11.22 deletion, this
enrichment could also facilitate the identification of homozygotes in whom the phenotypic
impact of such variants is more extreme.
Large-scale implementation of the above strategy for identifying high-impact variants must
address the concern that standard methods of controlling for population stratification may
not work well for rare variants38. Such stratification is unlikely to be a major issue in our
study for several reasons. First, in Northern Finland the 22q11.22 deletion has an allele
frequency of ~3-5%, and thus is not a rare variant. Second, stratification is of less concern in
populations, where substructure has a clear geographical basis38, and where fine-grained
information is available about the geographical origin of the study subjects is available, as is
the case in multiple Finnish cohorts; several studies have demonstrated the high degree of
correlation, in such cohorts, between geographical origin and measures of stratification
obtained from genome wide SNP data2, 39. Additionally, implementation of newly
developed methods for correcting for stratification at rare variants40 may facilitate
application of our strategy to a wider range of populations.
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The population impact in Northern Finland of the 22q11.22 deletion is likely much greater
than yet recognized, given its frequency there and its association with quantitative measures
of neurocognitive impairment. The predominant effect of the 22q11.22 deletion appears to
be on measures of neurocognitive function rather than on risk for specific diagnostic entities,
as evidenced by the range of phenotypes displayed by the homozygous deletion carriers, and
within the population cohort in which we have observed trait-associations. It may be feasible
to more precisely delineate the phenotypic effect of this deletion, as well as other deletions
that could have a similar effect, by obtaining more complete neurocognitive assessments in
larger samples from the Northern Finland population. The accumulation of deletion
genotype-phenotype associations that cut across classical disease categories has the potential
to enhance our understanding of mechanisms underlying disorders of brain and behavior.
For example, our results suggest that large-scale investigations of deletions in schizophrenia
study samples phenotyped for neurocognitive measures may contribute to the genetic
dissection of this phenotypically heterogeneous syndrome.
The phenotypic impact of the deletion reported here likely derives from its effect on TOP3β;
the deletion directly disrupts this gene, down regulates its mRNA levels, and does not
appear to alter transcript levels of genes outside the deletion region. This interpretation is
consistent with the findings from a recent report of a single individual, of unspecified ethnic
origins, who demonstrated speech delay and minor physical abnormalities and carried a
deletion that appears to be identical to the one presented here18. Analysis of animal models
with a genetically equivalent mutation may help clarify whether Top3β plays an important
role in synaptic plasticity.
Although the deletion also incorporates IGLV2-14, and we cannot exclude the possibility
that its loss contributes to the phenotypes that describe here, it is merely a predicted
transcript of unknown function, for which no independent mutations have been reported in
either the literature or databases. In contrast, recent surveys of de novo mutations have
yielded both direct and indirect genetic evidence suggesting that TOP3β missense variants
contribute to schizophrenia and autism spectrum disorders16, 17. The independent forms of
genetic evidence represented by the deletions and de novo variants, are complementary, and
taken together strengthen the suggestion that TOP3β plays an important role in
neurodevelopment.
Biochemical analysis revealed that TOP3β is part of a heterotrimeric TOP3β-TDRD3-
FMRP (TTF) complex. Similar to our study, an accompanying paper shows that Top3β
interacts with FMRP via TDRD3, and demonstrates that Top3β modifies dFMR1 function in
the Drosophila neuromuscular junction synapse formation41. Our data suggest a stepwise
model for TTF formation (Fig. S7a): TDRD3 reads aDMA marks on histones and
RNAPII33, 34, a process that recruits a TDRD3-TOP3β heterodimer to the TSS. After
binding of FMRP, the resulting heterotrimeric complex transfers to an EJC on the nascent
transcript. Thus, in this scenario, the recruitment of FMRP into mRNPs does not require
direct binding of FMRP to mRNA. Instead, recognition of aDMA marks at the TSS by
TDRD3 determines whether the resulting transcript is a target for FMRP. In line with this
conclusion, the genes bound by TDRD3 at their TSS overlap significantly with those that
acquire FMRP as a component of their mRNPs (Fig. S7b). Our data further show that other
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routes of FMRP recruitment to mRNPs must exist, as FMRP-containing mRNPs still form in
TDRD3 deficient cells, and our model does not rule out that FMRP – after being bound to
the EJC – directly contacts its target mRNAs, offering an explanation for the unexpected
observation that FMRP binding sites are dispersed throughout the coding regions on many
transcripts12, 42. In addition, this model predicts that, in the absence of TOP3β, mRNPs that
normally contain TTF are loaded only with a TDRD3-FMRP heterodimer (Fig. S7a).
The fate of the EJC-bound TTF complex, and the functional consequences of this interaction
are currently unknown. TTF-containing mRNPs associate with CBP20/80 but not with
eIF4E, suggesting a role of TTF during the pioneer round of translation32. EJC-associated
factors like the RNA surveillance complex or the protein kinase S6K1 rigorously control this
step. The latter is – like the TTF complex – specifically recruited to the EJC, increasing the
translational efficiency of the pioneer round43. S6K1 phosphorylates FMRP and is an
effector of the mammalian target of the rapamycin (mTOR) pathway, which controls
activity-dependent translation in neurons44. The EJC might hence serve as a molecular
scaffold to integrate the actions of FMRP and mTOR in regulated neuronal translation.
We note that the TTF complex bears striking similarity to the BLM-TOP3α-RMI1 complex
(BTR)45, implicated in the catalytic dissolution of replication-induced DNA four-way
junctions46. Similar four-way junctions present in RNA can be interconverted into kissing
complexes, which are known FMRP binding sites47, 48. Our data hence raise the possibility
that TOP3β remodels FMRP binding sites. Nevertheless, other functions of TOP3ß in
mRNA metabolism or even in completely unrelated cellular processes also appear feasible
and deserve further investigation.
The identification of TTF uncovered an unexpected biochemical link between Fragile X
patients and TOP3ß deletion carriers. This discovery raises two alternative scenarios: 1)
Neurodevelopmental disorders traditionally considered distinct share common etiologies;
under this scenario, the dysregulation of TTF-containing mRNPs may underlie the
overlapping neurocognitive impairment phenotypes observed in Fragile X syndrome and
schizophrenia. 2) Alternatively, different mutations in TOP3ß that affect different functions
of the gene result in different forms of psychopathology, and it is possible that deletion of
this gene contributes to neurodevelopmental phenotypes through as yet unidentified non-
FMRP pathways.
Future biochemical and enzymatic analyses of pathogenic TOP3ß missense mutations may
enable us to reject one or the other of these scenarios. However the second scenario implies
a greater level of specificity and certainty with respect to the definition and etiology of
neuropsychiatric syndromes, than is suggested by currently available data. For example,
Fragile X syndrome and schizophrenia share important phenotypic features that make it
unsurprising that they could also share underlying biological processes. Deficits in working
memory and other executive functions are perhaps the most salient neurocognitive features
of schizophrenia49, and are also frequently observed in Fragile X males50. Impairment in
cognitive function is also a feature of autism spectrum disorders, and it is possible that
FMRP-related abnormalities contribute to cognitive dysfunction in all of the disorders under
discussion here. The systematic identification of neuronal TTF mRNA targets and their
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functional analysis in relation to neuronal plasticity will help to clarify whether this is the
case.
Online Materials and Methods
The study samples
Table S1 summarizes features of the study samples. The relevant local and/or national
ethical review committees approved all of the studies contributing samples. All participants
provided written informed consent.
Sub-isolate Population Sample—The Sub-isolate Population Sample consisted of 173
participants, selected from FINRISK, a periodic nation-wide health survey cohort of
randomly selected, representative population samples from different parts of the country,
focused on risk factors for chronic and noncommunicable diseases19. The 1997 and 2007
surveys included individuals from Northeastern sub-isolate municipalities. We selected all
FINRISK participants with both parents originating from the sub-isolate for the Sub-isolate
Population Sample.
Whole Finland Population Sample—Individuals in the Whole Finland Population
Sample (N = 1,586) participated in the Helsinki Birth Cohort Study (HBCS), drawn from
8,760 individuals born in the Helsinki Central Hospital between 1934 and 1944, who
attended child welfare clinics in Helsinki, and lived in Finland in 1971. The individuals
comprising the Whole Finland Population Sample participated in a clinical study of HBCS
that involved collection of DNA samples from all participants.20
Sub-isolate and Whole Finland Schizophrenia Samples—The schizophrenia
subjects included in this study derived from three sources: the nationwide Finnish
Schizophrenia Family Study, the Health 2000 nationwide health survey (H2000), and the
Northern Finland Birth Cohort 1966 (NFBC 1966). Most of these subjects (N = 566) derived
from the Finnish Schizophrenia Family Study, in which the investigators used three national
registers, the Hospital Discharge Register, the Free Medicine Register and the Pension
Register to identify 33,731 individuals diagnosed schizophrenia between 1969-1998, drawn
from a cohort of individuals born between 1940 and 1976. Treating physicians contacted
potential probands; for those who provided written informed consent, they also contacted
additional family members. Independent review of materials by psychiatrists blind to the
family structures led to consensus best-estimate lifetime diagnoses according to the criteria
of the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV)25.
The 566 subjects selected from the schizophrenia study were members of independent
nuclear families. The Sub-isolate Schizophrenia Sample included 171 of these individuals
who originated from the Northeastern Finland sub-isolate. The Whole Finland
Schizophrenia sample included those who originated outside of the sub-isolate (N=395). We
identified the rest of the Finnish schizophrenia subjects included in this study (14 in the Sub-
isolate Schizophrenia Sample, and 72 in the Whole Finland Schizophrenia Sample) among
participants of H2000 and NFBC1966 diagnosed with DSM III-R or DSM IV schizophrenia
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or schizoaffective disorder using multiple sources of information, including structured
clinical interviews and medical records.
Sub-isolate Control Sample and Whole Finland Control Sample—These samples
are distinct from those that we used to investigate regional differences in deletion
frequencies, and consist of participants of nationwide Finnish health surveys and population
cohorts; NFBC1966, the Northern Finland 1986 Birth Cohort (NFBC1986), H2000, The
Cardiovascular Risk in Young Finns study (YFS), the Finnish Twin Cohort (FTC), and the
Dietary, Lifestyle and Genetic determinants of Obesity and Metabolic syndrome study
(DILGOM). The cohorts comprised altogether 11,871 individuals. Of these individuals, the
Sub-Isolate Control Sample included 747 who originated from the Northeastern Finland sub-
isolate, while the Whole Finland Control Sample included the remaining 11,124
individuals.. Descriptions of the individual cohorts are below.
Northern Finland 1966 and 1986 cohorts—The study subjects were members of two
prospective birth cohorts consisting of 96% and 99% of all live-born children in the two
most Northern provinces of Finland in 1966 and between July 1985- June 1986 (NFBC1966
and NFBC1986, respectively)10, 51. NFBC1966 began with collection of prenatal clinical
data on 12,068 live born children and has continued with follow-ups at multiple time points
that generated a phenotype data base combining information from official registers, hospital
records, questionnaires and clinical examinations of the participants. The present study
included 4931 genotyped individuals from this cohort10, 59 with a DSM-III-R based
diagnosis of schizophrenia or schizoaffective disorder, and 4872 without such diagnoses
(members respectively of either the Sub-isolate Schizophrenia Sample/Sub-isolate Control
Sample or Whole Finland Schizophrenia Sample/Whole Finland Control Sample, depending
on their parents’ birthplace). We additionally used the 4872 “controls” to evaluate the
relationship between the 4q12 and 22q11.22 deletions and other neurodevelopmental
phenotypes previously examined in this cohort in relation to larger deletions10.
NFBC1986 consists of 9,340 live born children, prospectively followed since their 12th
gestational week. The last follow-up to date, at age 16 years (years 2001-2002), included
6645 individuals who gave consent to participate in the study. The Sub-isolate Control
Sample includes NFBC1986 individuals (N=212), with both grandparents originating from
the Northeast Finland sub-isolate51.
Health 2000—Health 2000 (H2000) is a nationally representative cross-sectional health
study carried out in 2000 - 2001 and includes 8028 individuals. We selected 2,402 H2000
participants for the current study as follows: The majority (N=2212) were cases and controls
from a sub-study of genetic risk factors for metabolic syndrome, of whom 27 met DSM-IV
diagnosis for schizophrenia or schizoaffective disorder, included as cases in the present
study52. The remaining 190 individuals were controls in a large European schizophrenia
consortium, SGENE53.
The Cardiovascular Risk in Young Finns Study—The Cardiovascular Risk in Young
Finns Study (YFS) is a follow-up study of cardiovascular risk factors from childhood to
adulthood, in study participants randomly chosen from the Population Register and recruited
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from five university cities in Finland. The baseline study launched in 1980 and included
3596 individuals. Follow-ups have occurred on average every three years, most recently in
2007, when participants were 27 years old. The present study included 2308 individuals
from YFS with available GWAS data54.
Finnish Twin Cohort (FTC)—We ascertained 1492 individuals (one twin, chosen
randomly, per pair) from the genotyped participants of the Finnish Twin Cohort, FTC. The
FTC includes both monozygotic and dizygotic twins, collected in several separate phases.
The older cohort included 13,888 same-sex and 8000 opposite sex pairs with known
zygosity. The younger Finnish twin cohorts, referred to as FinnTwin12 and FinnTwin16, are
longitudinal studies of behavioral development and health habits of Finnish twins enrolled at
ages 11-12 and 16, respectively. These cohorts included 4913 pairs of both monozygotic and
dizygotic pairs55.
Dietary, Lifestyle and Genetic determinants of Obesity and Metabolic
syndrome study (DILGOM)—A subset of individuals, aged between 25 and 74, from the
FINRISK 2007 health survey participated in the DILGOM sub study. The present study
included the 612 genotyped individuals from DILGOM as members of the Whole Finland
Control Sample56.
The International Schizophrenia Consortium (ISC)—The ISC sample consisted of
3,391 schizophrenia subjects, diagnosed according to DSM-IV or ICD 10, and 3181
controls, all of European origin. A previous publication detailed the data set and the CNV
Calls (obtained using Birdseye, from the intensity data of the genotype probes on the
Affymetrix 5.0 and 6.0 genotyping arrays23.
The Swedish Schizophrenia Cohort (SSC)—The SSC sample included individuals in
Sweden hospitalized at least twice for schizophrenia since 1973 (N= 5785). The SSC
controls (N = 6348), group matched with the cases regarding age, sex, and county of
residence had no hospitalization due to psychiatric diagnoses.
GWAS and CNV calling—Genome-wide genotyping studies utilized the following
arrays: Illumina Human670K customBeadChip (HBCS, NFBC1986, YFS, FT TWINS,
DILGOM, and parts of the Schizophrenia Family Study sample), Illumina Infinium
HDHuman610-Quad BeadChip (DILGOM and the majority of the H2000 sample), Illumina
HumanHap300 Chip (the remainder of the schizophrenia subjects and H2000 controls,
included in the SGENE consortium), Illumina HumanHap370 Chip (NFBC1966), and
Affymetrix 5.0 and 6.0 genotyping arrays (ISC and SSC). We utilized QuantiSNP57 and
PennCNV58 software to make CNV calls, employing the LogR Ratio (LogRR) and B-allele
frequency (BAF) of SNP probes included in the genotyping arrays. We called CNVs
independently for each cohort and carried out QC based on graphical clustering of LogRR or
BAF standard deviations, removing outlier samples from each cohort. In all cohorts we
excluded individuals if their LogRR or BAF standard deviations were over 0.35 and 0.07,
respectively; waviness factor was outside the range −0.04 - 0.04; and BAF drift exceeded
0.002, according to software recommendations.
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We conducted a genome-wide scan for deletions (>20 kb in size) in the Sub-isolate and
Whole Finland Population Samples, reading deletion genotypes from QuantiSNP and
including only deletions with > 10 probes and Bayes factor over 10. To ensure reliable high
quality data, we visually inspected the intensity distributions for deletions that showed
significant deviation in frequency between the Sub-isolate and Whole Finland samples and
tested them for Hardy-Weinberg equilibrium. For the other data sets we utilized deletion
calls intersecting the previously identified regions on chromosomes 4 and 22. We validated
the 22q11.22 in a subset of 258 individuals (19 carrying the deletion) with Sequenom
MassARRAY and quantitative real-time PCR (QRT-PCR). The deletion genotypes had
100% correspondence with those from GWAS arrays.
Statistical analysis—We discarded from the analysis breakpoints including more than 88
overlapping deletions (frequency > 5%) in the 1,759 individuals. We used PLINK
software59 to cluster individuals to sub-isolate and whole Finland groups, according to
parental origin; compare the frequencies of deletions (>20 kb, at the start and end point of
each deletion) between the Sub-isolate Population Sample and the Whole Finland
Population Sample; and calculate allelic Chi-square p-values. We calculated empirical p-
values after 10,000 permutations for each deletion breakpoint. For testing associations with
schizophrenia and other traits we used allelic Fisher exact tests and Conchran-Mantel-
Haenszel statistics.
Gene expression analysis—Using an Illumina HumanHT-12 v4 Expression BeadChip
we generated genome-wide gene expression data for 65 individuals from 18 families of the
Finnish Schizophrenia Family Study, at the FIMM Technology Centre. To study the direct
impact of the 22q11.22 deletion on TOP3B, we studied its average expression levels (probe
4900386) in heterozygous carriers (N = 12 individuals), homozygous carriers (N = 2), and
non-carriers (N = 51), and used R (MA-ANOVA program package) to analyze the effect of
carrying this deletion on genome-wide gene expression levels, including. only the 9872
probes that showed signal above background levels in all individuals. Since this analysis
was exploratory, we derived q-values to determine if any of the observed significant changes
have occurred beyond the level of false discovery. The pathway analysis carried out for 813
genes (858 probes) showed nominal statistical difference (p < 0.05) between deletion
carriers and non-carriers, using the functional annotation tool in DAVID bioinformatics
resources 6.760.
Antibodies—A previous publication described the primary antibody against FMRP14.
Purchased primary antibodies include: FLAG (Sigma # A2220), HA (HISS # MMS-101R),
GFP (Roche # 11814460001), TDRD3 (Bethyl # A310-983A), TOP3β (Abcam # ab56445),
PABPC1 (Abcam # ab21060), GAPDH (Abcam # ab9485), HISTONE H3, rpL7 (Abcam #
72550), MAGOH (Santa Cruz # sc-271405), CBP80 (Santa Cruz # sc-271304) and CBP20
(Santa Cruz # sc-48793), eIF2γ (Proteintech # 11162-1-AP), eIF4E (Abcam # ab1126).
Plasmids and mutagenesis—We cloned cDNAs of TDRD3 (wt or truncations) and
TOP3β in a pcHA/DNA5/FRT/TO plasmid (Invitrogen) containing an N-terminal FLAG-tag
(for stable cell line preparation), a pGEX-6P-1 Vector containing a C-terminal 6xHis-stop
Stoll et al. Page 15













sequence (for protein expression) or a pEGFP C1 vector (for immunocytochemistry or IP),
and introduced point mutations and deletions into the individual constructs by PCR
mutagenesis.
Cell culture, plasmid transfections—The culture medium for all cells was DMEM
containing 10% FCS and 1% Pen/Strep (PAA). Stable cell line medium additionally
contained balsticidin and hygromycin (both Invivogen); tetracycline addition (1:2000) 5h
prior to harvesting induced protein-expression in these cells. We carried out all transfections
using Nanofectin™ (PAA). Generation and cultivation of HEK293 FlpTRex cell lines
(Invitrogen) was according to manufacturer’s instructions. We purchased the TDRD3
deficient human lung adenocarcinoma cell line JCRB0814 [VMRCLCD] from the JCRB
Cell Bank of the National Institute of Biomedical Innovation.
Immunocytochemistry and stress treatment—For immunocytochemistry and stress
treatment we followed procedures described previously16. We treated cells with 50 ng/ml
Leptomycin B for 3 h to block nuclear export.
Co-immunoprecipitations (IPs)—We performed IPs with 25μl of α-FLAG M2 agarose
(Sigma) or protein-G Sepharose (GE-Healthcare) bound α-GFP-antibodies (Roche) per ml
cell extract. After adding lysis buffer (150 mM NaCl, 50 mM Tris pH 7.5, 2.5 mM MgCl2
and 0.5% NP40, 0.5 mM DTT, protease inhibitors) and incubation on ice for 10 min, we
cleared extracts by centrifugation (11000 rpm, 10 min, 4°C) before IP for 1 h (4°C).
Subsequent to extensive washing of the beads with lysis buffer, we eluted precipitated
complexes with 1% SDS (15 min, 70°C) and subjected them to SDS PAGE and Western
blot. Dounced and cleared mouse brain homogenate (in ice-cold IP lysis buffer, see above)
served for immunoprecipitations, with the indicated antibodies bound to Protein G-
Sepharose (GE Healthcare).
Cross-linking and immunoprecipitation (CLIP)—We grew HEK293 FlpTRex-
TOP3β cells or HEK293 control cells on 15cm plates to ~90% confluency and UV-cross-
linked them 5 h later (254 nm, CL-1000 Ultraviolet Crosslinker). We then incubated
harvested cells with lysis buffer containing protease inhibitors (50 mM HEPES pH 7.5, 150
mM KCl, 2 mM EDTA, 0.5% NP40, 1 mM DTT) for 10 min on ice. After lysate clearing
(11000 rpm, 10 min, 4°C), a treatment with RNAse T1 followed (1:10000, 7 min, 22°C)
(Ambion 1000 U/μl). We cooled the extracts subsequently on ice for 5min and incubated
them with pre-equilibrated magnetic FLAG M2 agarose (SIGMA) (1 h, 4°C). We then
washed the beads (washing conditions: 50 mM HEPES pH 7.5, 300 mM KCl and 0,05%
NP40) before adding different RNAse T1 concentrations (1:100000, 1:10000, 1:1000 or
1:100) and repeated the washing procedure ( 3x with high salt buffer (50 mM HEPES pH
7.5, 500 mM KCl, 0,05% NP40 and 3x with phosphatase buffer (10 mM Tris-HCl pH.8, 100
mM KCl, 5 mM MgCl2 and 0.2% Triton X-100). Dephosphorylation of co-precipitated
RNAs occurred within 40 min at 37°C using Fast AP (Fermentas). We 5′-labeled RNAs on
washed beads using [γ-32P] ATP (Perkin Elmer) and PNK (Fermentas) (1 h, 37°C). After
additional washing 5x with labeling buffer, we boiled the beads in SDS sample buffer and
subjected eluates to gel electrophoresis (NuPAGE Bis-Tris 4-12%, Life Technologies) and
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subsequent Western blotting on nitrocellulose. α-FLAG antibodies enabled us to detect
precipitated FLAG/HA-TOP3β, and exposing the blot membrane to an X-ray film allowed
the detection of the RNA.
oligo(dT) pulldown—We performed oligo(dT) pulldown assays using oligo(dT) cellulose
(Fluka) according to manufacturer’s instructions. We analyzed the oligo(dT) bound mRNPs
by SDS-PAGE and Western blot as described above either after Mock-treatment or after
digestion with RNAse A. (Qiagen).
Cleavage assays—We labeled RNA
(GGGAUUAUUGAACUGUUGUUCAAGCGUGGU) or DNA
(GGGATTATTGAACTGTTGTTCAAGCGTGGT) oligomers at the 5′-end using [γ-32P]
ATP (Perkin Elmer) and PNK (Fermentas) (1 h, 37°C) or at the 3′-end using [5′-32P] pCp
and T4 RNA Ligase (Fermentas) (over night at 4°C). For cleavage assays, we incubated ~
40 fmol of radiolabeled oligomers with recombinant TOP3β wildtype or active site mutant
(Y336F) (amounts are indicated in the individual experiment) at 42°C in buffer containing
40 mM HEPES pH6.5, 10% PEG400, 40% glycerol, 1 mM MgCl2, 1 mM DTT and 10
μg/ml BSA for 2 min. SDS at a final concentration of 0,2 % and incubation for 1 min
stopped the reaction. We analyzed release of 5′-fragments on 12% UREA PAA-Gels, and
covalent 3′-labeled TOP3β-RNA intermediates on a 10% SDS PAA-Gel. Detection of
recombinant TOP3β occurred via Western blotting using anti-TOP3β antibodies, detection
of RNAs via autoradiography.
Cell fractionation and gradient centrifugation—We used the Qproteome cell
compartment kit (Qiagen) to prepare nuclear and cytoplasmic extracts from HeLa cells
according to manufacturer’s instructions. A previous study described translation factor
purification31 except that we dounced cells and pelleted ribosomes in a Beckman 45Ti rotor
(4 h, 40000 rpm, 4°C). For polysome gradient centrifugations (5-45% sucrose) we lysed
cells in a buffer containing 100 mM KCl, 20 mM Tris pH 7.5, 5 mM MgCl2, 0.5% NP40, 1
mM DTT, 100 μg/ml cycloheximide and protease inhibitors and extracts clarified (11000
rpm, 10 min, 4°C) and subjected extracts to centrifugation in an SW60Ti rotor (Beckman)
(1:35 h, 34500 rpm, 4°C). UV profiling [A254nm] served to control ribosomal
sedimentation and we analyzed individual fractions by SDS PAGE and Western blot.
Protein expression and pulldown assays—We expressed indicated proteins in E. coli
BL21 Rosetta II (500 ml of TB medium supplemented with glucose (20 g/l) and antibiotics
at 30°C to 0.4 OD600, and expression conditions were 4 h at 18°C after induction with 0.5
mM IPTG). We resuspended pelleted cells in lysis buffer (20 mM HEPES pH8, 500 mM
KCl, 5 mM EDTA, 5 mM β-mecaptoethanol (β-ME) and 10% glycerin, protease inhibitors
1:1000), sonified them and prepared a cleared lysate (1 h, 35000 rpm, 4°C) in a Beckman
45Ti rotor. Addition of 200 μl of pre-equilibrated Glutathion-Sepharose (GE-Healthcare) to
the supernatant and incubation for 2 h at 4°C lead to binding of recombinant protein to the
matrix. After extensive washes, we eluted bound proteins with 50 mM glutathione. In the
subsequent purification, we incubated 200 μl of Ni2+-NTA (Qiagen) matrix with the pooled
elution fractions for 2 h at 4°C, followed by washing with lysis buffer containing 10 mM
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imidazole. Elution of boundprotein occurred in 20 mM HEPES pH8, 100 mM KCl, 5 mM β-
ME, 500 mM imidazole and 10% glycerin. For TDRD3-TOP3β interaction studies, we
prepared TDRD3 as described above (cleavage of the GST-tag occurred via incubation with
PreScission protease (GE Healthcare) at 4 U/μl for 5 h at 4°C prior to the Ni2+-NTA
purification step. For in vitro binding assays, we incubated immobilized GST-TOP3β-6xHis
with TDRD3-6xHis (1 h, 4°C) and washed 3x with buffer containing 20 mM HEPES pH 8,
300 mM KCl and 0.5% NP40. We analyzed the bound complexes by SDS-PAGE and
Coomassie staining. For wildtype or mutant GST-TDRD3-6xHis pull-down assays from cell
lysates we immobilized equal amounts of protein on Glutathion-Sepharose and incubated
them with HeLa extracts prepared as described above (see IP section). Analyis of
precipitated proteins occurred via SDS-PAGE and Western blot.
We expressed catalytically active recombinant GST-TOP3β-6xHis in Sf21 insect cells. For
this step, we transformed E. coli DH10EMBacY with a pACEBac1 transfer plasmid
carrying GST-TOP3β-6xHis (wildtype or active site mutant (Y336F)), using the resulting
recombinant bacmid DNA for transfection of Sf21 cells using Cellfectin II Reagent
(Invitrogen). A typical expression was in 200 ml culture volume (2×106 cells per ml) for
72h. We then sonicated harvested cells in lysis buffer (750 mM KCl, 20 mM Tris-HCl pH
7.5, 10% glycerin, 1 mM EDTA, 0.05% NP40, 1 mM DTT and protease inhibitors 1:500)
and cleared lysates by centrifugation (45 min, 25000 rpm, 4°C). We performed affinity
purification as described above.
Comparison of FMRP PAR-CLIP and TDRD3 Chromatin IP data—We inferred
known protein coding genes associated with TDRD3 from a genome-wide TDRD3
chromatin IP dataset33, and FMRP targets from a recent study that used photoactivatable
ribonucleoside enhanced crosslinking and IP (PAR-CLIP) as well as ribonucleoprotein
immunoprecipitation followed by microarray analysis (RIP-chip) to define human FMRP
bound mRNAs42. Transcripts considered FMRP targets contained at least one identified
binding site and showed enrichment in the RIP-chip (log fold enrichment > 0.1). We
assessed statistical significance of the overlap (i.e. FMRP target transcripts of TDRD3-
bound genes) using a Chi-square test with Yates’ correction.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. The frequency of neurodevelopmental disorders in Finland varies by region.
This variation corresponds to the migration history of the Finnish population, as exemplified
by schizophrenia prevalence4, 6, 7 (Fig. 1A) and by the percentage of the population with a
disability pension due to intellectual disability (Official Statistics of Finland, the Social
Insurance Institution of Finland, 2011) (Fig. 1B). Black arrows depict the radiation of
migration, beginning in the 16th century, from the early settlement region to the late
settlement region (the border of the two regions is outlined in light grey). Red arrows show
the location of sub-isolate municipalities within the Northeastern late settlement region.
Gradients in prevalence of neurodevelopmental disorders, across different municipalities,
are shown by the intensity of the blue shading.
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Figure 2. The 22q11.22 deletion covers about 240 kb, is present in homozygous form in
individuals diagnosed with schizophrenia and/or cognitive deficits, and results in dose-dependent
reduction in TOP3β.
(a). A schematic representation of 22q11.2 (17 −22.0 Mb) depicts the distinct regions
containing the deletions implicated in VCFS and the distal 22q11.22 deletion syndrome; the
latter region includes the 240 kb deletion described in this paper. Orange bars depict known
disease-related genes (based on OMIM) as well as genes relevant for the current study. Grey
bars represent low copy repeats associated with the deletions in this region, while blue bars
show the most common syndrome-related deletions18and the 240 kb 22q11.22 deletion
reported here. The SNPs defining the breakpoint are marked above the deletion. The
breakpoint region between the SNPs is marked with dashed lines. The deletion is flanked by
two complementary low- copy repeats (grey bars). The genes located on the deletion region
are presented below the deletion, which incorporates the full extent of TOP3β and
IGLV2-14. Genomic positions are according to hg build 36. (b). Four individuals with
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homozygous 22q11.22 deletions, all of whom display schizophrenia and/or intellectual
impairment, are members of three pedigrees from Northern Finland. The pedigrees, which
include two documented consanguineous matings, are presumed to descend from a common
ancestor (dashed line) based upon the common 22q11.22 haplotype observed among all of
the homozygous deletion carriers. (c) TOP3β mRNA levels differ among non-carriers,
heterozygous carriers and homozygous carriers of the 22q11.22 deletion. The expression
level of TOP3β in non-carriers (269.99, 95%-CI = 249.18 - 290.79) was twice that of
heterozygotes (127.61, 95%-CI = 103.92- 151.30), while homozygous deletion carriers had
no detectable transcript.
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Figure 3. TOP3β is part of a cytosolic, mRNP-associated protein complex that contains TDRD3
and FMRP.
(a) Immunoprecipitation of FLAG/HA-TOP3β from stably transfected HEK293 cells led to
the co-purification of TDRD3 and FMRP in an RNAse-insensitive manner. In contrast,
RNAse abolished the association of TOP3β with the mRNP proteins PABPC1 and
MAGOH. (b) The TTF complex is present in neuronal cells. Immunoprecipitations from
mouse brain lysates using antibodies directed against TDRD3 (lane 3) or TOP3β (lane 4).
Precipitated TTF components were immunodetected as indicated. Specificity was controlled
by an immunoprecipitation with pre-immune serum (lane 2). (c) Immunostaining of
untreated (CTR; upper panel) and arsenite treated (+ARS; lower panel) HeLa cells with an
anti-TOP3β antibody (green); nuclei were counterstained with DAPI (blue). TOP3β was
localized predominantly in the cytosol where it showed a diffuse staining pattern. Arsenite
treatment led to its accumulation in cytosolic foci that resemble stress granules (see also Fig.
S3). Scale bars represent 50 μm. (d) TOP3β binds mature mRNAs. Cells expressing
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FLAG/HA-TOP3β were lysed in the presence of SDS (lane 1, input) and polyadenylated
RNA was purified by affinity to oligo(dT) cellulose (lane2). This led to the co-purification
of TOP3β and the known RNA binding proteins FMRP and PABPC1, while the control
protein GAPDH was not found in the eluate. Treatment of the lysate with RNAse A prior to
oligo(dT) affinity purification (lane 3) diminished binding of TOP3β, FMRP and PABPC1.
(e) TOP3β is in direct contact with RNA. Control cells (lane 1) or FLAG/HA-TOP3β-
expressing cells (lanes 2-6) were crosslinked using UV light (lanes 1-5) or left untreated
(lane 6). FLAG/HA-TOP3β was immunoprurified under stringent conditions and
crosslinked RNAs were treated with increasing amounts of RNAse T1 prior to 5′-labeling
with [γ32P]-ATP. Middle panel: Autoradiography of [32P]-labeled RNA crosslinked to
FLAG/HA-TOP3β. Lower panel: Western blot control of immunoprecipitated FLAG/HA-
TOP3β. All images are representative of at least 3 independent experiments; full-length
blots and gels are presented in Figure S8.
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Figure 4. TOP3β catalyzes RNA transesterification.
(a) Schematic of the reaction mechanism. TOP3β binds to a substrate oligonucleotide and a
cleavage-religation equilibrium is established, leading to the transient formation of a 5′-
fragment and a covalent complex with a tyrosyl-5′-phosphodiester bond between the 3′-
fragment and the enzyme. Addition of SDS to the reaction intermediate leads to a release of
the cleaved 5′-fragment and the covalent complex. (b) Coomassie stain of purified
recombinant wildtype TOP3β and an active site mutant (Y336F). (c) TOP3β is active on
DNA oligonucleotides and can be competed off by addition of RNA. A single stranded, 5′-
[32P] labeled DNA oligo was incubated with TOP3β, the reaction was stopped with SDS
and cleavage products were analyzed by denaturing polyacrylamide gel electrophoresis and
autoradiography. Cleavage was observed for wildtype TOP3β (wt; lanes 1-3) but not for an
active site mutant (lane 4). Addition of cold competitor RNA resulted in a strong inhibition
of the reaction (lanes 2 and 3). (d) TOP3β cleaves RNA. A 5′ [32P] labeled RNA oligo was
incubated with TOP3β either in Y336F mutant (lane 2) or wildtype (lane 6) form and
cleavage products were analyzed as in (b). To control for impurities in the recombinant
protein preparations that might lead to unspecific RNA fragmentation, wildtype and Y336F
mutant protein were titrated against each other (lanes 3-5). (e) TOP3β forms a covalent
tyrosyl-5′-phosphodiester bond with RNA. Cleavage reactions using the indicated amounts
of TOP3β were performed like in (c) except that 3′-[32P] labeled RNA was used. Formation
of the TOP3β-RNA covalent complex was monitored by denaturing SDS-PAGE and
autoradiography (upper panel). As a control, TOP3β protein was detected by Western blot
(lower panel). (f) The TOP3β-RNA covalent complex is present in cellular extracts. Proteins
bound to polyadenylated RNAs were affinity-purified by oligo(dT) cellulose as described in
figure 4e, except that RNAse A treatment was performed not in the extract but after elution
of from the column. This revealed high molecular weight species migrating above
FLAG/HA-TOP3β, which were recognized by the anti-FLAG antibody. These were
enriched by oligo(dT) purification and sensitive to RNAse treatment, indicating for covalent
FLAG/HA-TOP3β-RNA complexes. SDS-PAGE of input (lane 1) and eluates either
untreated (lane2) or treated with RNAse (lane 3) was analyzed by and Western blotting.
Proteins of interest were immunodetected using the indicated antibodies. All images are
Stoll et al. Page 27













representative of at least 3 independent experiments; full-length blots and gels are presented
in Figure S8.
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Figure 5. The TTF complex is present on early mRNPs that undergo the pioneer round of
translation.
(a) Schematic of the ribosome salt wash (RSW) used to purify proteins associated with the
translational machinery. Fractions used in (b) are underlined. (b) RSW of HeLa cells
analyzed by SDS-PAGE with subsequent Coomassie staining (left panel) and Western blot
against the indicated marker proteins (right panel). Immunodetection shows that endogenous
TDRD3 and TOP3β co-purify with translation initiation factor eIF2γ in the high salt
supernatant (S500), indicating that they are indirectly associated with ribosomes via
translating mRNPs.(c) Polysome gradient analysis of extracts from a stable cell line
expressing FLAG/HA-TDRD3. RNA profiling (upper panel) and Western blot analysis of
gradient fractions (lower panel) revealed that the TTF-complex components co-sediment
with polyribosomes in an RNAse sensitive manner (d) TTF-bound mRNPs show
characteristics of early mRNPs that have not yet undergone steady state translation. Extracts
of control cells (lane 1) or FLAG/HA-TDRD3 expressing cells (lane 2) were subjected to
anti-FLAG IP to purify TTF-bound mRNPs either without (lanes 3 and 5) or with (lanes 4
and 6) RNAse pretreatment. The TTF complex was associated with ribosomal RNAs and the
nuclear cap binding proteins CBP80 and CBP20 but not eIF4E in an RNAse sensitive
manner. All images are representative of at least 3 independent experiments; full-length
blots and gels are presented in Figures S8 and S9.
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Figure 6. Formation of the TTF complex is essential for the co-recruitment of TOP3β and FMRP
into mRNPs.
(a) Schematic of the TDRD3 mutants that were used to analyze the biogenesis of TTF-
containing mRNPs. (b) Recognition of aDMA by the TDRD3 Tudor domain is required for
efficient TTF complex formation in vivo. The indicated mutants were immunoprecipitated
and co-precipitated proteins were analyzed by Western blotting. Note that the residual
FMRP signal is RNAse sensitive for TDRD3ΔFIM but not for TDRD3TDRmut, indicating
that in the latter case the TTF complex was formed, albeit with an efficiency lower to that of
wildtype TDRD3 (see Fig. S5c)..(c) Tudor-mutant TDRD3 can still bind mRNPs. HeLa cell
extracts (input; lane 1) were incubated with purified recombinant GST-TDRD3-6xHis either
in wildtype (lane 2), Tudor-mutant (lane 3) or EBM-mutant (lane 4) form. GST-6xHis was
used as a control (lane 5). Upper panel: Coomassie-stained bait proteins. Lower panels:
Western Blot detection of FMRP and MAGOH. (d) Recruitment of TOP3β to mRNPs
requires binding of TDRD3 to the EJC. Analysis of extracts from a cell line carrying a
deletion of TDRD3 (ΔTDRD3) by sucrose gradient centrifugation revealed that the
association of TOP3β with polysomal mRNPs was disrupted. Polysomal migration of
TOP3β was restored by transfection of wildtype, but not EBM-mutant TDRD3. Lower
panel: Quantification of polysomal TOP3β from three independent experiments; error bars:
SD. (e) TDRD3 is essential for the co-recruitment of FMRP to TOP3β-containing mRNPs.
TDRD3-negative cells were co-transfected with GFP-TOP3β and either a control
(FLAG/HA) or FLAG/HA-TDRD3 in ΔFIM-mutant or wildtype form. GFP-TOP3β-
containing mRNPs were immunoprecipitated and analyzed for co-precipitated proteins by
Western blotting with the indicated antibodies. While co-transfection of ΔFIM-mutant
TDRD3 enabled the formation of mRNPs containing GFP-TOP3β (lane7), a co-recruitment
of FMRP was observed only when wildtype TDRD3 was transfected (lane8). All images are
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representative of at least 3 independent experiments; full-length blots and gels are presented
in Figure S9.
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Table 1
Association of the 22q11.22 deletion with schizophrenia
22q11.22 Deletion
Sample cases CTRLs Frequency OR (95%-CI) p-value
Finland, Sub-isolate 185 747 0.03 1.84 (1.05-3.23) 0.031
Finland, Whole 467 11124 0.003 2.63 (1.28-5.59) 0.0078
Europe, ISC and SSC 9176 9529 0.0005 2.17 (0.81-5.80) 0.12
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Table 2
Neurodevelopmental phenotypes among non-schizophrenic carriers of the 22q11.22
deletion in NFBC1966 (N=4,872)
Frequency 22q11 deletion alleles**
Phenotype Affected Unaffected Affected Unaffected OR (95%-CI) P (Fisher)
Psychosis* 0.02 0.004974 0/1/24 1/46/4778 4.08 (0.55-30.17) 0.2242
Intellectual disability 0.02174 0.004811 1/1/67 0/46/4735 4.60 (1.41-14.96) 0.03227
Repeated grades in school 0.01777 0.004513 1/5/191 0/42/4611 3.99 (1.78-8.94) 0.003399
Epilepsy 0 0.005132 0/0/76 1/47/4726 0 (0-inf) 1
Neonatal convulsions 0.002392 0.005171 0/1/208 1/46/4594 0.46 (0.06-3.35) 0.7239
Cerebral palsy and/or perinatal brain damage 0.008475 0.005009 0/1/58 1/46/4744 1.70 (0.23-12.40) 0.4519
Impaired Hearing at 14 years old 0.005814 0.005024 0/2/170 1/45/4632 1.16 (0.28-4.79) 0.6927
*
Includes individuals with diagnoses of bipolar disorder, depression with psychotic features, or other psychotic disorders, excluding schizophrenia
and organic psychosis.
**
Homozygous carriers/heterozygous carriers/ non-carriers
Nat Neurosci. Author manuscript; available in PMC 2014 April 15.
